National Centre for Pharmacoeconomics

National Centre for

NCPE Ireland

Tisagenlecleucel (Kymriah®). HTA ID: 22044

Tisagenlecleucel (Kymriah®) is indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy.


NCPE Assessment Process Complete
Rapid review commissioned 28/06/2022
Rapid review completed 27/07/2022
Rapid Review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of tisagenlecleucel compared with the current standard of care.